Midwest Biomedical Accelerator Consortium: MBArC

总结 NIH快速加速诊断（RADx）计划支持美国国家努力开发 准确、快速、用户友好和可访问的COVID-19感染检测。中西部生物医学 加速器联盟（MBArC）是五个国家研究评估和商业化中心之一 由NIH资助的REACH中心，支持将新的科学发现转化为商业产品 诊断、预防和治疗影响美国人口的高负担疾病。这样做的目的 行政补充请求是为了利用RADx和REACH计划高度一致的目标 通过支持三个有前途的科学团队，他们将开发新颖和创新的技术， 用于诊断COVID-19感染的护理设备。每个科学团队都将获得资金，以进行证明- 概念和产品定义研究。MBArC中心的领导层将与每个团队密切合作， 帮助他们实现他们的里程碑并降低他们的技术风险。MBArC领导层将连接 资助团队的MBArC中心和REACH网络的学术和教育资源。MBArC 领导层还将与NIH工作人员密切合作，以促进受资助团队和RADx的成功 倡议

SUMMARY The NIH Rapid Acceleration of Diagnostics (RADx) initiative underpins the US national effort to develop accurate, rapid, user-friendly, and accessible testing for COVID-19 infection. The Midwest Biomedical Accelerator Consortium (MBArC) is one of five national Research Evaluation And Commercialization Hub (REACH) centers funded by NIH to support the translation of novel scientific discoveries into business products that diagnose, prevent, and treat high-burden diseases affecting the US population. The purpose of this administrative supplement request is to leverage the highly aligned goals of the RADx and REACH programs by supporting three promising scientific teams that will develop novel and innovative technologies into point-of- care devices for diagnosing COVID-19 infection. Each scientific team will receive funding to perform proof-of- concept and product definition studies. The leadership of the MBArC hub will work closely with each team to assist them in achieving their milestones and de-risking their technologies. MBArC leadership will connect funded teams to the academic and educational resources of the MBArC hub and REACH network. MBArC leadership will also work closely with NIH staff to promote the success of the funded teams and the RADx initiative.